New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Discover what makes Paris's biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...